Keyword: Johnson & Johnson

As flights from China contract and prices double, the logistics of getting products out of China is a major challenge. 

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Boehringer and Lilly's Jardiance is locked in a Type 2 diabetes battle against its SGLT2 rivals, and a leg up in Type 1 now doesn't appear likely.

With drugmakers on the hunt for a COVID-19 therapeutic, Johnson & Johnson said repurposing HIV med Prezista might not do the trick.

As COVID-19 spreads, pharma's forcing sales reps to stay at home, subbing digital tools and virtual meetings for face-to-face physician visits.

J&J CAR-T partner Legend aims for U.S. IPO. The FDA's not sure how many drugs and APIs come from China. Harbour teams with Mount Sinai on coronavirus.

Aiming to keep pace with its SGLT2 rivals in kidney disease, Lilly and Boehringer's Jardiance scored a speedy FDA review in the indication.

The state of New York will delay a key opioid bellwether trial in a move that could free drugmakers to aggressively pursue global settlements.

Amid a year of legal challenges over opioids and baby powder, Johnson & Johnson CEO Alex Gorsky nabbed a more than $5 million pay bump in 2019.